AstraZeneca’s PARP inhibitor Lynparza was successful in improving progression free survival in a Phase 3 trial of patients with metastatic prostate cancer.
The drug met its primary endpoint in the Phase 3 PROfound trial of men with metastatic castration-resistant prostate cancer (mCRPC) who have a *homologous recombination repair gene mutation (HRRm) and have progressed on prior treatment with new hormonal anticancer treatments (e.g. enzalutamide and abiraterone).
